After months of dismissal, Shoker learned his symptoms were stage 4 Hodgkin lymphoma. Now he’s sharing his journey and hope ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to UB-VV111 for the treatment of ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

To confirm a diagnosis and determine the stage of the disease, your doctor will use a series of tests: Biopsy: This is the most definitive test. A surgeon will remove all or part of an affected lymph ...

New research challenges the status quo that cancer treatments are responsible for accelerating the aging process, indicating that cancer itself also plays a role. A team of researchers from Moffitt ...

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet need “For people with relapsed or refractory mantle ...

Please provide your email address to receive an email when new articles are posted on . The FDA denied glofitamab as second-line DLBCL therapy, noting insufficient evidence for U.S. population.

The FDA issued a complete response letter for glofitamab-gxbm plus gemcitabine and oxaliplatin (GemOx) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), citing insufficient STARGLO trial ...

Brexucabtagene autoleucel approval marked a significant advancement in MCL treatment, achieving a 62% complete remission rate in resistant or relapsed patients. Prognostic tools like the Ki-67 index ...